Data for drugs available through low-cost prescription drug programs are available through pharmacy benefit manager and claims data
- PMID: 22726249
- PMCID: PMC3416643
- DOI: 10.1186/1472-6904-12-12
Data for drugs available through low-cost prescription drug programs are available through pharmacy benefit manager and claims data
Abstract
Background: Observational data are increasingly being used for pharmacoepidemiological, health services and clinical effectiveness research. Since pharmacies first introduced low-cost prescription programs (LCPP), researchers have worried that data about the medications provided through these programs might not be available in observational data derived from administrative sources, such as payer claims or pharmacy benefit management (PBM) company transactions.
Method: We used data from the Indiana Network for Patient Care to estimate the proportion of patients with type 2 diabetes to whom an oral hypoglycemic agent was dispensed. Based on these estimates, we compared the proportions of patients who received medications from chains that do and do not offer an LCPP, the proportion trend over time based on claims data from a single payer, and to proportions estimated from the Medical Expenditure Panel Survey (MEPS).
Results: We found that the proportion of patients with type 2 diabetes who received oral hypoglycemic medications did not vary based on whether the chain that dispensed the drug offered an LCPP or over time. Additionally, the rates were comparable to those estimated from MEPS.
Conclusion: Researchers can be reassured that data for medications available through LCPPs continue to be available through administrative data sources.
Figures
Similar articles
-
Utilization and Costs of Compounded Medications for Commercially Insured Patients, 2012-2013.J Manag Care Spec Pharm. 2016 Feb;22(2):172-81. doi: 10.18553/jmcp.2016.22.2.172. J Manag Care Spec Pharm. 2016. PMID: 27015256 Free PMC article.
-
Impact of type 2 diabetes mellitus on prescription medication burden and out-of-pocket healthcare expenses.Diabetes Res Clin Pract. 2010 Mar;87(3):360-5. doi: 10.1016/j.diabres.2009.11.021. Epub 2010 Jan 4. Diabetes Res Clin Pract. 2010. PMID: 20047768
-
Assessing changes in third-party gross margin for a single community pharmacy.J Am Pharm Assoc (2003). 2014 Jan-Feb;54(1):27-34. doi: 10.1331/JAPhA.2014.13083. J Am Pharm Assoc (2003). 2014. PMID: 24362541
-
Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.Pharmacoeconomics. 2004;22(6):389-411. doi: 10.2165/00019053-200422060-00005. Pharmacoeconomics. 2004. PMID: 15099124 Review.
-
Economic and clinical impact of innovative pharmacy benefit designs in the management of diabetes pharmacotherapy.Am J Manag Care. 2007 Apr;13 Suppl 2:S55-8. Am J Manag Care. 2007. PMID: 17417934 Review.
Cited by
-
Estimation of Missed Statin Prescription Use in an Administrative Claims Dataset.J Manag Care Spec Pharm. 2017 Sep;23(9):936-942. doi: 10.18553/jmcp.2017.23.9.936. J Manag Care Spec Pharm. 2017. PMID: 28854076 Free PMC article.
-
Quantification of missing prescriptions in commercial claims databases: results of a cohort study.Pharmacoepidemiol Drug Saf. 2017 Apr;26(4):386-392. doi: 10.1002/pds.4165. Epub 2017 Jan 25. Pharmacoepidemiol Drug Saf. 2017. PMID: 28120552 Free PMC article.
-
Assessing Medicare Part D claim completeness using medication self-reports: the role of veteran status and Generic Drug Discount Programs.Med Care. 2015 May;53(5):463-70. doi: 10.1097/MLR.0000000000000341. Med Care. 2015. PMID: 25793271 Free PMC article.
References
-
- Choudhry NK, Shrank WH. Four-Dollar Generics — Increased Accessibility, Impaired Quality Assurance. N Engl J Med. 2010;363(20):1885–1887. doi: 10.1056/NEJMp1006189. Available at http://www.nejm.org/doi/pdf/10.1056/NEJMp1006189. Accessed September 5, 2011. - DOI - DOI - PubMed
-
- Kaiser Family Foundation and Health Research and Education Trust. Employer health Benefits: 2009 annual survey. 2011. Available at: http://ehbskfforg/pdf/2009/7936pdf. Accessed June 17.
-
- Czechowski JL, Tjia J, Triller DM. Deeply discounted medications: Implications of generic prescription drug wars. J Am Pharm Assoc (2003) 2010;50(6):752–757. doi: 10.1331/JAPhA.2010.09114. Available at: http://japha.metapress.com/media/f6pnujmwlrnfd7nwdrwq/contributions/h/6/.... Acessed September 5, 2011. - DOI - PubMed
-
- AHRQ. Health Information Exchange. 2009. Available at: http://www.healthit.ahrq.gov/hie. (accessed May 2012)
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
